Geneos Wealth Management’s CollPlant Biotechnologies CLGN Stock Holding History

Geneos Wealth Management’s Portfolio CLGN Stock Details CLGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-750	Closed	-$4.22K	–	2108
2023 Q3	$4.22K	Hold	750	–	–	﹤0.01%	1793
2023 Q2	$6.08K	Hold	750	–	–	﹤0.01%	1694
2023 Q1	$5.26K	Hold	750	–	–	﹤0.01%	1714
2022 Q4	$6.26K	Hold	750	–	–	﹤0.01%	1657
2022 Q3	$5K	Hold	750	–	–	﹤0.01%	1679
2022 Q2	$6K	Hold	750	–	–	﹤0.01%	2121
2022 Q1	$8K	Buy	+750	New	+$8.25K	﹤0.01%	2163

Other funds holding CLGN

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

BFEC

Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Geneos Wealth Management's CLGN Position: Q4 2023 in Review

Geneos Wealth Management sold out of CollPlant Biotechnologies (CLGN) in Q4 2023, closing a stake of 750 shares — an estimated $4.22K sold.

Geneos Wealth Management first reported a position in CLGN in Q1 2022 and held it in 7 quarters. The position peaked at $8K in Q1 2022. 17 funds tracked by Wall St. Rank hold CLGN as of Q4 2023.

Geneos Wealth Management reported no remaining CollPlant Biotechnologies position as of Q4 2023 after selling out during the quarter.
Geneos Wealth Management sold 750 CollPlant Biotechnologies shares in Q4 2023, an estimated $4.22K.
Geneos Wealth Management first reported a position in CollPlant Biotechnologies in Q1 2022 and held it in 7 quarters.
Geneos Wealth Management's CollPlant Biotechnologies position peaked at $8K in Q1 2022.
17 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q4 2023.

Based on Geneos Wealth Management's 13F filing for Q4 2023, filed 26 Jan 2024.